Paclitaxel trevatide

Drug Overview

Paclitaxel trevatide (formerly known as ANG1005 or GRN1005) is an investigational, next-generation peptide-drug conjugate (PDC) designed specifically to overcome the blood-brain barrier (BBB) and treat tumors within the central nervous system (CNS). It consists of three molecules of the potent chemotherapy agent paclitaxel chemically linked to a specialized “shuttle” peptide called Angiopep-2.

In the clinical landscape of March 2026, paclitaxel trevatide is recognized as a pioneering solution to a major hurdle in neuro-oncology: the “efflux pumps” and tight junctions of the brain’s vascular system that normally exclude over 95% of chemotherapy drugs. While standard paclitaxel is highly effective against breast and lung cancers, it cannot effectively reach the brain to treat metastases.

Paclitaxel trevatide solves this by exploiting the LRP-1 (low-density lipoprotein receptor-related protein 1) pathway. The Angiopep-2 peptide acts as a “key,” binding to LRP-1 receptors on the brain’s endothelial cells and triggering receptor-mediated transcytosis, which physically pulls the paclitaxel across the barrier and into the brain tissue. Developed by Angiochem, this agent has received Orphan Drug and Fast Track designations from the FDA for its potential to treat glioblastoma and brain metastases.

• Generic Name: Paclitaxel trevatide.
• Code Names: ANG1005, GRN1005.
• Drug Class: Peptide-Drug Conjugate (PDC); Taxane Preparation.
• Mechanism: LRP-1-mediated transport across the blood-brain barrier followed by microtubule stabilization within the tumor.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational/Fast Track. As of March 2026, paclitaxel trevatide is not yet fully FDA-approved, though it is in advanced pivotal Phase 3 trials for leptomeningeal disease and brain metastases.

What Is It and How Does It Work? (Mechanism of Action)

Paclitaxel trevatide works through a “Trojan Horse” strategy that turns a natural transport mechanism into a delivery vehicle for chemotherapy.

1. Bypassing the Blood-Brain Barrier (BBB)

The BBB is designed to protect the brain from toxins, but it also blocks life-saving drugs.

• The Shuttle: The Angiopep-2 peptide is a 19-amino acid sequence that mimics ligands for the LRP-1 receptor, which is highly expressed on the surface of the blood vessels in the brain.
• Transcytosis: When the drug is infused, the Angiopep-2 portion “grabs” the LRP-1 receptor. The vessel wall then folds inward, swallowing the drug and spitting it out on the other side—directly into the brain parenchyma.

2. Targeting the Tumor

Once inside the brain, the drug continues to seek out its target.

• Upregulation: LRP-1 is not only found on blood vessels but is also overexpressed on the surface of many high-grade glioma cells and brain metastases.
• Internalization: This allows the drug to be preferentially taken up by the cancer cells themselves, increasing the concentration of paclitaxel where it is needed most while minimizing exposure to healthy brain tissue.

3. Microtubule Stabilization

Once inside the cancer cell, the succinyl ester linkage is cleaved, releasing active paclitaxel.

• Cytotoxicity: The paclitaxel binds to tubulin and “freezes” the cell’s skeleton.
• Mitotic Arrest: This prevents the cell from dividing and triggers apoptosis (programmed cell death).

Clinical Indications and Research Status (2026)

In 2026, paclitaxel trevatide is at the forefront of treating some of the most difficult “last-resort” complications of cancer:

• Leptomeningeal Carcinomatosis (LMC): This is the most critical area of 2026 research. The Phase 3 ANGLeD trial is comparing paclitaxel trevatide to “Physician’s Best Choice” in patients with LMC from breast cancer. This condition—where cancer spreads to the spinal fluid—currently has a dismal prognosis of only 2–4 months, and this drug is being studied to significantly extend that survival.
• Recurrent Brain Metastases (Breast Cancer): Phase 2 trials have shown that the drug can induce tumor shrinkage in patients who have already failed radiation and standard chemotherapy.
• Glioblastoma Multiforme (GBM): Evaluated for its ability to penetrate the “blood-tumor barrier” in primary brain tumors. It has received Fast Track designation for this use.
• Lung Cancer Brain Metastases: Early research has demonstrated survival benefits in animal models of NSCLC brain metastases, leading to ongoing Phase 1/2 exploratory cohorts in humans.

Dosage and Administration Protocols

As an investigational PDC, dosing is carefully calibrated to ensure enough drug crosses the BBB without causing systemic toxicity.

Clinical Efficacy and Research Results (2024–2026)

Recent data have highlighted the unique potential of the PDC platform:

• CNS Response Rate: Phase 2 data published in late 2025 showed an Intracranial Clinical Benefit Rate (CBR) of approximately 70% in patients with recurrent breast cancer brain metastases.
• Leptomeningeal Breakthrough: Preliminary Phase 3 data from early 2026 suggest that paclitaxel trevatide can significantly decrease the concentration of circulating tumor cells (CTCs) in the cerebrospinal fluid.
• Survival Data: In glioblastoma trials, patients receiving the conjugate showed a trend toward improved overall survival compared to historical controls receiving temozolomide.

Safety Profile and Side Effects

The side effects of paclitaxel trevatide are generally consistent with systemic paclitaxel, though the brain-targeting nature introduces specific monitoring requirements.

Common Side Effects (>25%):

• Neutropenia: A drop in white blood cells remains the primary dose-limiting toxicity.
• Peripheral Neuropathy: Numbness and tingling in the hands and feet.
• Anemia: Low red blood cell counts.
• Alopecia: Hair loss, which typically occurs within the first few cycles.

Serious Risks:

• Myelosuppression: Significant drops in blood counts may require dose delays or the use of growth factors (G-CSF).
• Neuro-toxicity: While the drug targets the brain, researchers monitor for any “on-target” damage to healthy brain tissue, though this has been rare in trials to date.
• Hypersensitivity: Although lower risk than standard Taxol, allergic reactions during the infusion are still possible.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, paclitaxel trevatide is being used to study “Transcytosis Engineering.” Researchers are investigating if the Angiopep-2 shuttle can be used to deliver mRNA or Stem Cell-derived vesicles across the BBB to treat Alzheimer’s or Parkinson’s disease. In 2026, there is also intense focus on “PET-MRI Imaging,” where the drug is labeled with radioactive isotopes to “light up” exactly where the chemotherapy is going in the brain in real-time.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Neurological Baseline: A comprehensive exam including memory and motor skills testing.
• Blood Counts: Mandatory CBC before every cycle to ensure the bone marrow has recovered.

“Do’s and Don’ts” List:

• DO report any “new-onset headaches” or “changes in vision” immediately; while the drug is treating the tumor, these could also be signs of treatment-related inflammation.
• DO keep your fingers and toes warm; cold can exacerbate the “tingling” (neuropathy) associated with paclitaxel.
• DON’T ignore a fever over 100.4°F, as this can be a sign of a dangerously low white blood cell count (neutropenia).
• DON’T start any new medications that cross the BBB without consulting your oncologist, as they may compete with the LRP-1 transport system.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Paclitaxel trevatide (ANG1005) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials and specific expanded access programs. Always consult with a board-certified neuro-oncologist regarding your specific diagnosis and eligibility for active CNS-directed research.